立方制药：关于全资子公司取得药品注册证书的公告

Group 1 - The core point of the article is that Lifan Pharmaceutical announced that its wholly-owned subsidiary, Hefei Chengzhi Biopharmaceutical Co., Ltd., has received the drug registration certificate for Loxoprofen Sodium Oral Solution from the National Medical Products Administration [2] Group 2 - The approval of the drug registration certificate signifies a regulatory milestone for the company, potentially enhancing its product portfolio and market presence [2] - This development may lead to increased revenue opportunities for the company as it can now market and sell the approved medication [2] - The approval reflects the company's commitment to expanding its pharmaceutical offerings and meeting regulatory standards [2]